Sun Upbeat On IL-23 Prospects In US, Ilumya Faring ‘Reasonably’

Indian Firm’s China, Japan Plans Gather Pace

Sun expects interleukin-23-targeting drugs to stay a preferred treatment option for psoriasis in the US and saw some sales uptick for its Ilumya in that market in Q2, although it isn’t keen on an auto injector option. Management was also upbeat on prospects in China and Japan.

Jigsaw
India Business Lifts Sun In Q2 • Source: Shutterstock

Sun Pharmaceutical Industries Ltd. reported 16% growth in sales to INR79.49bn ($1.1bn) in the second quarter of fiscal 2020, buoyed by the India business, but a dull showing in the US took some sheen off the performance.

India sales rose 35% to INR25.15bn, though adjusted for an inventory correction in Q2 last year and on a comparable...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip